Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 180

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Phase 2 study of high‐dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer

Open access
Chang, Joe Y., Komaki, Ritsuko, Lu, Charles, Wen, Hong Y., Allen, Pamela K., Tsao, Anne, Gillin, Michael, Mohan, Radhe, Cox, James D.·2011·Cancer

Abstract

BACKGROUND: The authors sought to improve the toxicity of conventional concurrent chemoradiation therapy for stage III nonsmall cell lung cancer (NSCLC) by using proton‐beam therapy to escalate the radiation dose to the tumor. They report early results of a phase 2 study of high‐dose proton therapy and concurrent chemotherapy in terms of toxicity, failure patterns, and survival. METHODS: Forty‐four patients with stage III NSCLC were treated with 74 grays (radiobiologic equivalent) proton therapy with weekly carboplatin (area under the curve, 2 U) and paclitaxel (50 mg/m 2). Disease was staged with positron emission tomography/computed tomography (CT), and treatments were simulated with 4‐dimensional (4D) CT to account for tumor motion. Protons were delivered as passively scattered beams, and treatment simulation was repeated during the treatment process to determine the need for adaptive replanning. RESULTS: Median follow‐up time was 19.7 months (range, 6.1‐44.4 months), and median overall survival time was 29.4 months. No patient experienced grade 4 or 5 proton‐related adverse events. The most common nonhematologic grade 3 toxicities were dermatitis (n = 5), esophagitis (n = 5), and pneumonitis (n = 1). Nine (20.5%) patients experienced local disease recurrence, but only 4 (9.1%) had isolated local failure. Four (9.1%) patients had regional lymph node recurrence, but only 1 (2.3%) had isolated regional recurrence. Nineteen (43.2%) patients developed distant metastasis. The overall survival and progression‐free survival rates were 86% and 63% at 1 year. CONCLUSIONS: Concurrent high‐dose proton therapy and chemotherapy are well tolerated, and the median survival time of 29.4 months is encouraging for unresectable stage III NSCLC. Cancer 2011;. © 2011 American Cancer Society

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.26080

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 180

Metadata

Authors
Chang, J. Y., Komaki, R., Lu, C., Wen, H. Y., Allen, P. K., Tsao, A., Gillin, M., Mohan, R., & Cox, J. D.
Venue
Cancer
Publisher
Wiley
Published
2011-03-22
Volume
117
Issue
20
Pages
4707-4713
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1966418691
Cited by
180
References
1
FWCI
14.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 2 study of high‐dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. https://app.cochat.ai/papers/10.1002/cncr.26080
The paper
Chang, J. Y., Komaki, R., Lu, C., Wen, H. Y., Allen, P. K., Tsao, A., Gillin, M., Mohan, R., & Cox, J. D. (2011). Phase 2 study of high‐dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. https://doi.org/10.1002/cncr.26080

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.